SNDY Is About To Price In Its Latest Breaking Development
Good Morning!

Solos Endoscopy, Inc. (OTCPINK: SNDY)
A very bullish chart setup and a very breaking news development have created the prefect storm for you to capitalize on SNDY.
You might remember this play because I have alerted it in the past. In fact, it’s one of the most consistent winners I have delivered and I expect this time round to be no less lucrative.
Over the last few sessions a set of key technical factors have positioned SNDY for a potentially huge rally. First, SNDY is trading well below its 13-week high of .15. Based on my calculations at the time of writing, traders have around 200% upside opportunity on the table. SNDY is also trading below its 4-week high of .13 – the upside opportunity there is around 160%.
The second technical factor that is powering the bullish confidence in a SNDY breakout is its daily volatility. This has been rising in recent session and its most recent session saw a volume breakout of more than 53%.
You should also know that even after the wave of profit taking, SNDY is still holding a “buy” rating at Barchart.com. This fact shouldn’t be overlooked because it shows in no small way that SNDY has the requisite amount of upside potential to retain such a bullish rating.
The technicals alone are more than capable of making SNDY pop but the ace up your sleeve is the strong news just released by the company. SNDY has just resumed sales of its MammoView® Ductoscopy Instruments. This is extremely fresh news!
Get ready to move on SNDY right now because the combination of factors outlined is bound to make it pop.
Check out the chart…

Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/SNDY
About
SNDY (Solos Endoscopy, Inc.) is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
US Medical Device Set To Reach $133 Billion By The End Of 2016
The United States remains the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016. The U.S. market value represented about 38 percent of the global medical device market in 2012. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2012, a more than 7 percent increase from the previous year.
There are more than 6,500 medical device companies in the U.S., mostly small and medium-sized enterprises (SMEs). More than 80 percent of medical device companies have fewer than 50 employees, and many (notably innovative start-up companies) have little or no sales revenue. Medical device companies are located throughout the country, but are mainly concentrated in regions known for other high-technology industries, such as microelectronics and biotechnology. The states with the highest number of medical device companies include California, Florida, New York, Pennsylvania, Michigan, Massachusetts, Illinois, Minnesota and Georgia. Other states with significant sector employment include Washington, Wisconsin, and Texas.
News Development
Solos Endoscopy Fulfills Backorders for MammoView(R) Ductoscopy Instruments
SNDY has just announced that it has resumed sales of its MammoView® Ductoscopy Instruments as a result of its ability to fulfil all of its backorders, which were due to production issues experienced from one of its component manufacturers. The component manufacturer has resolved its production issue and has resumed its deliveries, on a timely basis, to Solos and is confident that it will not experience this issue in the future.
"The production issues have been successfully addressed and I'm confident in the uninterrupted sale and production of the MammoView® product line going forward," stated Robert Segersten, CEO.
Mammary ductoscopy is designed to provide physicians the means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging, which can reveal evidence of the disease. The Solos Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise. Solos' intraductal devices are designed to provide direct observation with any endoscopic video system while providing unprecedented image quality, using advanced minimally invasive technologies and tissue preservation techniques.
To learn more about SNDY please visit their website: http://www.solosendoscopy.com/
The bullish chart and the extremely fresh and important news are reasons enough for you to move on SNDY right now. Don’t miss out.
BEATPENNYSTOCKS